General
“In a 6-week randomized, double-blind, placebo-controlled trial of 100 adults aged 18–45 with dissatisfied sleep, 2 grams of magnesium L-threonate daily (145 mg elemental magnesium) improved cognitive performance by an amount researchers estimated was equivalent to a 7.5-year reduction in cognitive age, compared with placebo."…”
Plain restatementA single six-week randomized placebo-controlled trial in 100 adults aged 18 to 45 with self-reported poor sleep reported that 2 g/day of magnesium L-threonate produced a greater improvement on a composite cognitive test battery than placebo, and the authors converted that difference into an estimated 7.5-year "cognitive age" equivalent using normative decline rates.
This claim accurately describes a real study. A six week randomised, double blind, placebo controlled trial published in Frontiers in Nutrition in January 2026 gave 100 adults aged 18 to 45 with poor sleep either 2 grams of magnesium L-threonate daily or a placebo, and reported better overall cognitive test scores in the supplement group, which the authors converted into an estimated 7.5 year reduction in cognitive age. That 7.5 year number is an exploratory calculation, not a measurement: the two groups differed by 2.24 points on a cognitive composite, and the authors divided that by an assumed normal decline of 0.3 points per year. Two things the post leaves out matter. The study was funded by Threotech, the company that makes the branded Magtein ingredient tested, and the company helped design it and supplied the product. The supplement also showed no benefit on a reasoning test or on objectively measured sleep from a wearable ring. The post's headline image is also wrong on a basic fact, saying eight weeks when the trial ran six. This is one small, industry funded trial with results that sat just under the statistical significance threshold, so it is a reason for further research rather than a settled finding.
[drifted from the evidence:] In a [drifted from the evidence:] 6-week randomized, [drifted from the evidence:] double-blind, placebo-controlled trial [drifted from the evidence:] of 100 adults aged [drifted from the evidence:] 18–45 with [drifted from the evidence:] dissatisfied sleep, 2 [drifted from the evidence:] grams of magnesium L-threonate [drifted from the evidence:] daily (145 mg elemental magnesium) improved cognitive [drifted from the evidence:] performance by an [drifted from the evidence:] amount researchers estimated [drifted from the evidence:] was equivalent to a 7.5-year [drifted from the evidence:] reduction in cognitive age, [drifted from the evidence:] compared with placebo." (Accompanying image headline, also assessed: "Magnesium Reduces Brain Age by up to 7.5 years In Just 8 Weeks!")
A [added by the neutral restatement:] single six-week randomized placebo-controlled trial [added by the neutral restatement:] in 100 adults aged [added by the neutral restatement:] 18 to 45 with [added by the neutral restatement:] self-reported poor sleep [added by the neutral restatement:] reported that 2 [added by the neutral restatement:] g/day of magnesium L-threonate [added by the neutral restatement:] produced a greater improvement on a composite cognitive [added by the neutral restatement:] test battery than placebo, and the authors converted that difference into an estimated 7.5-year "cognitive age" [added by the neutral restatement:] equivalent using normative decline rates.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The trial exists, is peer reviewed, and is correctly cited by the post.
- 6 weeks, randomised, double-blind, placebo-controlled: correct.
- 100 adults, aged 18 to 45, with self-reported dissatisfied sleep: correct.
- 2 g daily magnesium L-threonate providing 145 mg elemental magnesium: correct.
- Greater improvement in overall cognitive performance versus placebo on the NIH Total Cognition Composite: correct as reported.
- The "7.5-year reduction in cognitive age" language comes from the authors themselves, not from the poster: correct.
- Improvements in reaction time, working memory and episodic memory: consistent with the paper.
- The caption's own caveats are accurate: the researchers measured test performance rather than brain structure or biological aging, the 7.5-year figure was exploratory, and the result is specific to magnesium L-threonate.
- Visual/headline mismatch (date and framing error): the post's lead image says "Reduces Brain Age by up to 7.5 years In Just 8 Weeks!" The trial ran six weeks, not eight, and measured estimated cognitive age from test scores, not brain age. The headline graphic is what most scrollers will see; the careful caption caveats appear only to those who expand the text.
- Omitted qualifier, funding: neither the claim text nor the caption discloses that the study was funded by Threotech Inc., the manufacturer of the branded ingredient tested, which also supplied the product and helped conceptualise the design. For a supplement efficacy claim this is material context.
- Omitted qualifier, selective outcomes: the claim reports the positive findings and omits that there was no effect on Raven's Progressive Matrices, no effect on objective sleep measures from the wearable, and no group difference in self-reported sleep disturbance. The win was partial, not across the board.
- Magnitude framing: "7.5 years" sounds large but derives from a 2.24-point difference on a composite score divided by an assumed 0.3-point annual decline. A small absolute difference is converted into an emotionally vivid number. The post does flag this as exploratory, which is to its credit, but the headline does not.
- Marketing intent: the post ends with a "Comment MAG" lead-generation call to action, and the underlying evidence is manufacturer-funded. This is promotional context, not neutral science communication.
- Temporal overreach in the wider framing: the slide 2 text asks which magnesium may "Slow Down Aging, And Help Prevent Dementia." The trial measured nothing about dementia risk, biological aging, or long-term outcomes.
- Whether the p-values were adjusted for multiple comparisons across the NIH Toolbox subtests and the many secondary outcomes. I did not retrieve explicit confirmation either way, and this materially affects how robust the borderline findings are.
- Whether "cognitive age" was a pre-registered outcome in ACTRN12624000379516 or added later. The paper labels it exploratory, which suggests it was not a primary endpoint, but I did not retrieve the registry record itself to confirm.
- Effect sizes and confidence intervals for the main composite outcome were not fully retrieved, only p-values and the 2.24-point group difference.
- Whether the finding replicates. The only closely comparable prior trial is a 12-week study in older adults with cognitive complaints that produced a similar style of estimate, roughly 9 years. Both come from the same commercial ingredient ecosystem. No independent, non-industry replication was found.
The study exists and is real. It is a six-week, two-arm, parallel-group, randomised, double-blind, placebo-controlled trial by Adrian Lopresti and Stephen Smith of Clinical Research Australia, published in Frontiers in Nutrition on 12 January 2026. One hundred adults aged 18 to 45 with self-reported dissatisfied sleep were randomised 50/50 to 2 g/day magnesium L-threonate (Magtein) or rice flour placebo, dosed as 1 g in the morning and 1 g about two hours before bed, delivering 145 mg elemental magnesium daily. Reported results: compared with placebo, the supplement group showed a greater improvement on the NIH Toolbox Total Cognition Composite (p = 0.043), with larger treatment effects on working and episodic memory, and a greater improvement in reaction time (p = 0.031). The paper reports "a 7.5-year reduction in estimated brain cognitive age." There were no group differences on Raven's Progressive Matrices 2 (p = 0.953). Self-reported sleep-related impairment improved more with the supplement (p = 0.043), but there were no group differences in self-reported sleep disturbance or in objective sleep measures from the Oura Ring. Resting heart rate and heart rate variability during sleep improved. Tolerability was high; four participants discontinued, two per arm.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.